NCT04183114View on ClinicalTrials.gov

Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

540

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

November 11, 2019

Study Completion Date

November 11, 2019

Conditions
Congenital Rubella InfectionMeasles
Interventions
BIOLOGICAL

Measles-Rubella vaccine Bio Farma

MR vaccine produced by Bio Frama with 3 consecutive batches

BIOLOGICAL

MR Vaccine SII

MR Vaccine produced by SII (Already registered in Indonesia)

Trial Locations (1)

60131

Child Health Dept. Dr. Soetomo Hospital, School of Medicine Airlangga Univ., Surabaya

Sponsors

Lead Sponsor

PT Bio Farma
All Listed Sponsors
lead

PT Bio Farma

INDUSTRY